Prostate Cancer Clinical Trials in Nashville

Showing 341-359 of 359 trials

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

NCT00286793

This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,

Prostate Cancer

Ascenta Therapeutics76 participantsStarted Feb 2006

Hot Springs, Arkansas, United States • Fort Meyers, Florida, United States • Chicago, Illinois, United States +10 more locations

COMPLETEDPhase 2< 1 mile

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

NCT00090376

In this phase II study, an investigative (not approved by the FDA) drug called GPI 1485 is being assessed to see if it can help preserve erectile function after prostatectomy.

ImpotenceProstate Cancer

Eisai Inc.240 participantsStarted Dec 2003

Phoenix, Arizona, United States • La Mesa, California, United States • Stanford, California, United States +22 more locations

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

Prostate Cancer Trials in Other Cities

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

Study of Individualized Amonafide to Treat Prostate Cancer

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

Other Conditions in Nashville